연구성과로 돌아가기
2023 연구성과별 연구자 정보 (1349 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Choi, Won Suk | Choi, WS | 2 | Korea Univ, Coll Med, Dept Internal Med, Div Infect Dis,Ansan Hosp, Ansan, South Korea | V-2730-2017 | Choi, Won | 0000-0001-5874-4764 | Choi, Won Suk | heejinmd@korea.ac.kr; | |
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Heo, Jung Yeon | Heo, JY | 3 | Ajou Univ, Sch Med, Dept Infect Dis, Suwon, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Kim, Eun Jin | Kim, EJ | 4 | Ajou Univ, Sch Med, Dept Infect Dis, Suwon, South Korea | KYP-2633-2024 | Kim, Hanjin | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Lee, Jin Soo | Lee, JS | 5 | Inha Univ, Coll Med, Dept Internal Med, Div Infect Dis, Incheon, South Korea | 0000-0002-1587-4961 | Lee, Yoonyeong | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Jung, Dong Sik | Jung, DS | 6 | Dong A Univ, Dept Internal Med, Div Infect Dis, Coll Med, Busan, South Korea | HOH-5826-2023 | Jung, Dong Sik | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Kim, Shin -Woo | Kim, SW | 7 | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Infect Dis,Dept Internal Med, Daegu, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Park, Kyung-Hwa | Park, KH | 8 | Chonnam Natl Univ, Dept Internal Med, Div Infect Dis, Med Sch, Gwangju, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Eom, Joong Sik | Eom, JS | 9 | Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Infect Dis,Coll Med, Incheon, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Jeong, Su Jin | Jeong, SJ | 10 | Yonsei Univ, Coll Med, Dept Internal Med, Div Infect Dis,Severance Hosp, Seoul, South Korea | 0000-0003-4025-4542 | Jeong, Su Jin | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Lee, Jacob | Lee, JC | 11 | Hallym Univ, Coll Med, Div Infect Dis, Dept Internal Med, Chunchon, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Kwon, Ki Tae | Kwon, KT | 12 | Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Div Infect Dis,Dept Internal Med, Daegu, South Korea | 0000-0003-4666-0672 | Kwon, Ki Tae | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Choi, Hee Jung | Choi, HJ | 13 | Ewha Womans Univ, Mokdong Hosp, Dept Internal Med, Div Infect Dis, Seoul, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Sohn, Jang Wook | Sohn, JW | 14 | Korea Univ, Coll Med, Dept Internal Med, Div Infect Dis,Ansan Hosp, Ansan, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Kim, Young Keun | Kim, YK | 15 | Yonsei Univ, Dept Internal Med, Div Infect Dis, Wonju Severance Christian Hosp, Yonsei, South Korea | H-4235-2013 | Kim, Young | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Yoo, Byung Wook | Yoo, BW | 16 | Soon Chun Hyang Univ Hosp, Dept Family Med, Seoul, South Korea | heejinmd@korea.ac.kr; |
페이지 이동: